Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA)De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With…
Growve, a leader in the health and wellness industry, announced today that it has secured a majority equity investment led by Palm Beach Capital (PBC), with participation from G-Bar Ventures and NMP Capital. As part of the transaction, Growve also closed on new debt…
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced the submission of the Marketing Authorization Application…
Nu Skin Enterprises (NUS: NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company’s board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. “Jim…
The NCSBN has released the NCLEX pass rates for Q1 of 2025 (January – March). Compared to Q1 of 2024, NCLEX pass rates have dropped in all categories. With large scale drops in both first time test takers and with…
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications…
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase…
City of Hope Atlanta, part of one of the largest and most advanced cancer research and treatment organizations in the United States, is calling for urgent change in light of surging cancer incidence among younger women. Central to the push:…
GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare’s…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and gemcitabine-oxaliplatin (R-GemOx)…
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced the presentations of trial-in-progress posters on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-cateninTCF4, at…
For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering…